Dr David Reynolds

David Reynolds is the CEO of two Dementia Discovery Fund-created companies AstronauTx and LoQus23 Therapeutics. AstronauTx is focused on modulating the function of astrocytes to treat Alzheimer’s and other neurodegenerative diseases. LoQus23 is targeting DNA damage repair processes which are a driving force of the pathophysiology in triplet repeat diseases like Huntington’s disease. David also provides his neuroscience expertise to the DDF team as a part-time Venture Partner.

Before that David was the CSO of Alzheimer’s Research UK, for 3 years. Previously David has worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience & Pain research site head. He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain. David holds a PhD from University of Cambridge and is a visiting Professor at the Institute of Neurology, University College London.